ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The German contract research organization Evotec has acquired Kinaxo, a Munich-based company that offers technologies for response prediction and safety assessment in drug development. Evotec will pay about $16 million and could make $5 million in additional payments depending on Kinaxo’s performance. Separately, Evotec will work with ChemBridge to expand its screening library. Evotec will enhance its library of 250,000 druglike compounds with an initial 110,000 compounds from ChemBridge.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X